Breaking News Instant updates and real-time market news.

ONCE

Spark Therapeutics

$81.88

1.37 (1.70%)

, BMRN

BioMarin

$89.84

-0.65 (-0.72%)

17:34
09/06/17
09/06
17:34
09/06/17
17:34

Spark named top pick in U.S. SMid-Cap Biotechnology at Barclays

Barclays analyst Gena Wang after the close initiated coverage of the U.S. Small & Mid Cap Biotechnology industry with a Positive view. Her top industry pick is Spark Therapeutics (ONCE). The analyst sees de-risking clinical data for several novel therapies in the biotech sector, namely from Spark, BioMarin (BMRN), AveXis (AVXS), Alnylam (ALNY) and Puma Biotechnology (PBYI). Wang believes Spark's Luxturna in RPE-65-mediated inherited retinal dystrophies could be disruptive to current treatment paradigms.

ONCE

Spark Therapeutics

$81.88

1.37 (1.70%)

BMRN

BioMarin

$89.84

-0.65 (-0.72%)

AVXS

AveXis

$92.59

1.72 (1.89%)

ALNY

Alnylam

$86.02

-0.78 (-0.90%)

PBYI

Puma Biotechnology

$99.10

2.25 (2.32%)

  • 06

    Sep

  • 06

    Sep

  • 07

    Sep

  • 08

    Sep

  • 09

    Sep

  • 11

    Sep

  • 12

    Sep

  • 04

    Oct

  • 18

    Oct

  • 12

    Jan

  • 28

    Feb

ONCE Spark Therapeutics
$81.88

1.37 (1.70%)

08/16/17
EVER
08/16/17
INITIATION
Target $83
EVER
In Line
Spark Therapeutics initiated with an In Line at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Spark Therapeutics with an In Line and a $83 price target.
09/06/17
LEHM
09/06/17
INITIATION
Target $104
LEHM
Overweight
Spark Therapeutics initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Spark Therapeutics with an Overweight rating and $104 price target. The analyst views the company's Luxturna as a potential disruptive treatment in inherited retinal dystrophies.
08/03/17
BMOC
08/03/17
NO CHANGE
BMOC
Spark Therapeutics price target raised to $89 from $69 at BMO Capital
BMO Capital analyst Matthew Luchini raised his price target on Spark as he thinks that Phase I/Phase II data on its SPK-8011 indicates that the drug "should be highly competitive with BioMarin's (BMRN) BMN-270." The analyst raised his estimate of SK-8011's success to 40% from 15%, and he reiterates an Outperform rating on the shares.
08/03/17
UBSW
08/03/17
NO CHANGE
Target $92
UBSW
Buy
Spark Therapeutics price target raised to $92 from $70 at UBS
UBS analyst Martin Auster raised his price target on Spark Therapeutics to $92 from $70 following compelling data for its hemophilia gene therapy results. The price target change reflects increased confidence in its overall gene therapy platform, said Auster, who reiterated his Buy rating on Spark Therapeutics shares.
BMRN BioMarin
$89.84

-0.65 (-0.72%)

09/06/17
LEHM
09/06/17
INITIATION
LEHM
Equal Weight
BioMarin assumed with an Equal Weight at Barclays
Barclays assumed BioMarin with an Equal Weight and $95 price target, citing a balanced risk/reward view.
08/16/17
EVER
08/16/17
INITIATION
Target $100
EVER
Outperform
BioMarin initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated BioMarin with an Outperform and a $100 price target.
08/30/17
08/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BioMarin (BMRN) initiated with a Buy at Citi. 2. Universal Display (OLED) initiated with a Buy at Deutsche Bank. 3. RE/MAX Holdings (RMAX) initiated with a Buy at Craig-Hallum. 4. Momo (MOMO) initiated with a Buy at Standpoint Research. 5. Community Bankers Trust (ESXB) initiated with a Hold at Sandler O'Neill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/30/17
SBSH
08/30/17
INITIATION
Target $98
SBSH
Buy
Citi starts BioMarin at Buy with $169 per share 'blue sky scenario'
Citi analyst Robyn Karnauskas started BioMarin with a Buy rating and $98 price target. The analyst sees approval of pegvaliase for the treatment of phenylketonuria, which has an FDA action date of February 28, 2018, as likely driving upside. BioMarin is an orphan disease company entering a period of profitability with three "controversial" programs, Karnauskas tells investors in a research note. The analyst believes pegvaliase is underappreciated by the street. Her "blue sky scenario" for BioMarin indicates fair value of $169 per share. The shares in premarket trading are up 4% to $85.9 after the company last night said the FDA accepted for priority review the biologics license application for pegvaliase.
AVXS AveXis
$92.59

1.72 (1.89%)

09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
AveXis initiated with an Overweight at Barclays
Barclays initiated AveXis with an Overweight rating and $124 price target, citing AVXS-101 showing "impressive" clinical benefit in Ph1/2 study, which could result in it becoming a strong competitor to Spinraza.
08/29/17
08/29/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Esperion (ESPR) initiated with an Outperform at Northland. 2. Carter's (CRI) initiated with an Outperform at Macquarie. 3. DarioHealth (DRIO) initiated with a Buy at Aegis. 4. Helen of Troy (HELE) initiated with an Underperform at BofA/Merrill. 5. AveXis (AVXS) initiated with a Reduce at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/28/17
NOMU
08/28/17
INITIATION
Target $52
NOMU
Reduce
AveXis initiated with a Reduce at Nomura Instinet
Nomura Instinet started AveXis with a Reduce rating and $52 price target.
08/23/17
08/23/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on the today's top five analyst initiations with this list compiled by The Fly: 1. HP Inc (HPQ) initiated with a Buy and HP Enterprise (HPE) initiated with a Hold at Loop Capital. 2. PTC (PTC), Autodesk (ADSK), ASpen Technology (AZPN) and SAP (SAP) initiated with Buy ratings and Trimble (TRMB) and ANSYS (ANSS) initiated with Hold ratings at Berenberg. 3. AveXis (AVXS) initiated with an Outperform at William Blair. 4. LivaNova (LIVN) initiated with a Hold at Needham. 5. Advanced Energy (AEIS) initiated with a Hold at Stifel. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ALNY Alnylam
$86.02

-0.78 (-0.90%)

09/06/17
LEHM
09/06/17
UPGRADE
LEHM
Overweight
Alnylam assumed with Overweight from Equal Weight at Barclays
Barclays assumed Alnylam with an Overweight from an Equal Weight with a price target of $105, up from $80, citing the likelihood of positive patisiran APOLLO Ph3 top-line data, as well as multiple pipeline programs providing long-term upside.
08/10/17
LEHM
08/10/17
NO CHANGE
Target $80
LEHM
Equal Weight
Alnylam price target raised to $80 from $50 at Barclays
Barclays analyst Geoff Meacham raised his price target for Alnylam Pharmaceuticals to $80 citing the recent positive data and commercial prospects for patisiran. The Phase 3 patisiran data is the key driver over the remainder of 2017, Meacham tells investors in a post-earnings research note. He believes trial success is likely. The analyst keeps an Equal Weight rating on Alnylam.
07/27/17
BERN
07/27/17
INITIATION
BERN
Outperform
Alnylam initiated with an Outperform at Bernstein
Bernstein analyst Vincent Chen started coverage of Alnylam with a $99 price target and an Outperform rating. He says that Alnylam " combines high-value late-stage assets with visible catalysts, and an increasingly de-risked RNA platform." The analyst adds that the company's assets are "high value and exciting," The analyst is upbeat on several of the company's late-stage therapies, including patisiran. He expects the latter therapy to obtain the "lion's share" of the TTR market.
07/17/17
LTCO
07/17/17
NO CHANGE
Target $90
LTCO
Buy
Alnylam price target raised to $90 from $80 at Ladenburg
Ladenburg Thalmann analyst Christopher James raised his price target for Alnylam Pharmaceuticals to $90 ahead of the upcoming Phase 3 APOLLO readout with patisiran. The analyst says his new target reflects increased confidence in a positive readout. He upped his probability of success for patisiran to 80% from 70% and keeps a Buy rating on Alnylam.
PBYI Puma Biotechnology
$99.10

2.25 (2.32%)

09/06/17
LEHM
09/06/17
INITIATION
Target $103
LEHM
Overweight
Puma Biotechnology initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Puma Biotechnology with an Overweight rating and $103 price target. The analyst sees "meaningful commercial opportunity" for the company's neratinib in the "very large" adjuvant breast cancer market.
08/10/17
JPMS
08/10/17
NO CHANGE
Target $105
JPMS
Overweight
Puma Biotechnology price target raised to $105 from $89 at JPMorgan
JPMorgan analyst Cory Kasimov raised his price target for Puma Biotechnology to $105 following the Q2 earnings report. The earnings contained nothing new ahead of the full launch of Nerlynx expected this September, Kasimov tells investors in a research note. The analyst continues to view Puma's "scarcity value" as attractive. He keeps an Overweight rating on the name.
08/01/17
LEER
08/01/17
NO CHANGE
LEER
Outperform
Puma selloff today brings buying opportunity, says Leerink
Puma Biotechnology shares are down 11% after the company announced last night that its lead product Nerlyx is commercially available by prescription in the United States. Puma has frequently been discussed as a potential takeover target, and some investors associate the availability of Nerylyx negatively with respect to the sales prospects of the company, Leerink analyst Michael Schmidt tells investors in an intraday research note. He says that while a potential buyout could yield near-term upside of 50%-75%, the timing of acquisitions are always difficult to predict accurately. Schmidt's thesis on the shares is based on underlying fundamentals, which he views as "compelling." The analyst reiterates an Outperform rating on Puma and recommends buying the stock on today's selloff. The shares in midday trading are down 11%, or $10.22, to $84.83.
08/01/17
LEER
08/01/17
NO CHANGE
LEER
Outperform
Puma Biotechnology selloff today a buying opportunity, says Leerink

TODAY'S FREE FLY STORIES

03:05
11/20/17
11/20
03:05
11/20/17
03:05
General news
FX Update: EUR-USD and euro crosses took a clobber »

FX Update: EUR-USD and…

TWX

Time Warner

$88.72

0.71 (0.81%)

, GE

General Electric

$18.21

-0.04 (-0.22%)

20:02
11/19/17
11/19
20:02
11/19/17
20:02
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

TWX

Time Warner

$88.72

0.71 (0.81%)

GE

General Electric

$18.21

-0.04 (-0.22%)

IBM

IBM

$148.97

-0.15 (-0.10%)

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

HMC

Honda

$32.62

0.02 (0.06%)

GLPG

Galapagos NV

$90.83

-0.66 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 14

    Dec

BABA

Alibaba

$185.13

-0.3 (-0.16%)

18:01
11/19/17
11/19
18:01
11/19/17
18:01
Hot Stocks
Alibaba, Auchan Retail, Ruentex form new retail strategic alliance »

Alibaba, Auchan Retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$88.72

0.71 (0.81%)

, CMCSA

Comcast

$36.16

-0.91 (-2.45%)

17:32
11/19/17
11/19
17:32
11/19/17
17:32
Hot Stocks
Box Office Battle: 'Justice League' wins weekend with just $96M »

Warner Bros.' (TWX)…

TWX

Time Warner

$88.72

0.71 (0.81%)

CMCSA

Comcast

$36.16

-0.91 (-2.45%)

CMCSK

Comcast

SNE

Sony

$46.17

0.07 (0.15%)

FOX

21st Century Fox

$30.48

1.88 (6.57%)

FOXA

21st Century Fox

$31.15

1.83 (6.24%)

LGF.A

Lionsgate

$32.59

1.55 (4.99%)

DIS

Disney

$103.44

-0.16 (-0.15%)

VIAB

Viacom

$26.15

2.46 (10.38%)

VIA

Viacom

$33.00

2.9 (9.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

17:10
11/19/17
11/19
17:10
11/19/17
17:10
Periodicals
GE yet to decide which directors will lose seats, WSJ reports »

A housecleaning at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLPG

Galapagos NV

$90.83

-0.66 (-0.72%)

17:01
11/19/17
11/19
17:01
11/19/17
17:01
Hot Stocks
Galapagos NV reports positive topline results from ALBATROSS with GLPG2222 »

Galapagos NV reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$262.26

-1.44 (-0.55%)

16:55
11/19/17
11/19
16:55
11/19/17
16:55
Hot Stocks
Boeing, Avolon finalize deal for 75 737 MAX airplanes »

Boeing and Avolon have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBLK

Star Bulk Carriers

$9.60

0.19 (2.02%)

16:53
11/19/17
11/19
16:53
11/19/17
16:53
Earnings
Star Bulk Carriers reports Q3 adjusted EPS (8c), consensus (5c) »

"We released today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

BDRBF

Bombardier

$2.43

0.0007 (0.03%)

16:22
11/19/17
11/19
16:22
11/19/17
16:22
Hot Stocks
Bombardier predicts Latin America's 60-150 seat aircraft fleet will double »

Bombardier Commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

TSLA

Tesla

$315.05

2.55 (0.82%)

10:21
11/18/17
11/18
10:21
11/18/17
10:21
Periodicals
Tesla new super car to cost $200,000, Recode says »

Alongside its new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 16

    Jan

GT

Goodyear Tire

$29.94

0.63 (2.15%)

10:17
11/18/17
11/18
10:17
11/18/17
10:17
Hot Stocks
Goodyear Tire, NASCAR extend relationship »

NASCAR and Goodyear Tire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Jan

  • 16

    Jan

HMC

Honda

$32.62

0.02 (0.06%)

10:05
11/18/17
11/18
10:05
11/18/17
10:05
Periodicals
Honda recalls 900,000 minivans on tip forward seats, Reuters says »

Honda Motor is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$88.43

-0.82 (-0.92%)

09:48
11/18/17
11/18
09:48
11/18/17
09:48
Periodicals
Activist investors Nelson Peltz still in P&G picture, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

, GE

General Electric

$18.21

-0.04 (-0.22%)

09:39
11/18/17
11/18
09:39
11/18/17
09:39
Periodicals
Buy Baker Hughes, Barron's says »

While it is "not…

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

GE

General Electric

$18.21

-0.04 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

CSCO

Cisco

$35.90

0.02 (0.06%)

09:19
11/18/17
11/18
09:19
11/18/17
09:19
Periodicals
More needed for Cisco to have 'groove back,' Barron's says »

While the Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

IBM

IBM

$148.97

-0.15 (-0.10%)

09:10
11/18/17
11/18
09:10
11/18/17
09:10
Periodicals
IBM could be next to fetch higher valuation, Barron's says »

Investors are warming to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

GE

General Electric

$18.21

-0.04 (-0.22%)

09:05
11/18/17
11/18
09:05
11/18/17
09:05
Periodicals
Option play offer some help given GE dividend, depressed stock, Barron's says »

While wagering against…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

09:00
11/18/17
11/18
09:00
11/18/17
09:00
Periodicals
Risk remains after GE dividend cut, Barron's says »

While buying General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$88.72

0.71 (0.81%)

, T

AT&T

$34.51

-0.01 (-0.03%)

08:21
11/18/17
11/18
08:21
11/18/17
08:21
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWX

Time Warner

$88.72

0.71 (0.81%)

T

AT&T

$34.51

-0.01 (-0.03%)

NYT

New York Times

$17.65

0.05 (0.28%)

TEX

Terex

$44.82

0.8 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

TPIC

TPI Composites

$19.06

-0.97 (-4.84%)

07:25
11/18/17
11/18
07:25
11/18/17
07:25
Conference/Events
TPI Composites to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SYNA

Synaptics

$38.21

0.57 (1.51%)

04:55
11/18/17
11/18
04:55
11/18/17
04:55
Conference/Events
Synaptics management to meet with KeyBanc »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.